Skip to main content
Premium Trial:

Request an Annual Quote

BioSeek to Study Compounds for UCB

NEW YORK (GenomeWeb News) - BioSeek said today it has entered into an agreement with the Belgian biopharmaceutical company UCB to evaluate drug compounds.
 
Under the agreement, BioSeek will use its BioMAP systems to support target differentiation, lead development, and drug-candidate selection activities for UCB compounds in several target classes. UCB is focused on developing therapeutics for central nervous system disorders, inflammation, and oncology.
 
The BioMAP systems are a series of primary cell-based assay systems used to replicate cell and pathway interactions involved in human disease.
 
Financial terms of the agreement were not released.
 

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.